- Giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer.
- The lidERA study results will be presented at the 2025 San Antonio Breast Cancer Symposium.
- ER-positive breast cancer accounts for about 70% of cases, with up to a third experiencing recurrence after treatment.
Study Overview
Roche's phase III lidERA Breast Cancer study evaluated giredestrant as an adjuvant endocrine treatment for ER-positive, HER2-negative, early-stage breast cancer. The study demonstrated that giredestrant significantly reduced the risk of invasive disease recurrence or death by 30% compared to standard-of-care endocrine therapy.
Key Findings
Giredestrant is the first oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking a significant advancement in endocrine therapy for breast cancer in over two decades. The hazard ratio was 0.70, with a 95% confidence interval of 0.57-0.87 and a p-value of 0.0014.
Implications
ER-positive breast cancer accounts for approximately 70% of all breast cancer cases, with up to a third experiencing recurrence after adjuvant endocrine therapy. The results suggest that giredestrant could become a new standard-of-care for early-stage ER-positive breast cancer, offering a more effective and tolerable treatment option.
Presentation and Future Steps
The lidERA study results will be presented at the 2025 San Antonio Breast Cancer Symposium and included in the official press program. Roche aims to share these findings with health authorities globally to expedite the availability of this new treatment option for patients.
